Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China flag China · Delayed Price · Currency is CNY
16.20
-0.28 (-1.70%)
Nov 17, 2026, 3:00 PM CST

SHA:600645 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3431,4231,5501,5381,5071,497
Other Revenue
32.1132.1135.8152.0747.837.94
1,3751,4551,5851,5901,5551,535
Revenue Growth
-6.56%-8.23%-0.27%2.24%1.27%16.41%
Cost of Revenue
409.36458.73497.75505.02510.29473.84
Gross Profit
966.09996.221,0881,0851,0451,061
Selling, General & Admin
627.15650.04695.33719.77723.4749.78
Research & Development
148.47149.01182.11184.49146.12133.85
Other Operating Expenses
19.2922.3419.3919.1917.5916.54
Operating Expenses
799.95843.04924.48946.57901.67937.05
Operating Income
166.14153.18163.2138.14142.93124.44
Interest Expense
-3.23-3.23-5.03-5.02-4.02-3.14
Interest & Investment Income
11.7117.924.429.5918.2316.21
Earnings From Equity Investments
-13.67-13.67-14.3-11.85-7.96-
Currency Exchange Gain (Loss)
4.594.59-3.21.51-2.370.1
Other Non Operating Income (Expenses)
7.360.1-3.221.03-2-1.49
EBT Excluding Unusual Items
172.9158.87161.84153.4144.82136.13
Impairment of Goodwill
------19.72
Gain (Loss) on Sale of Investments
7.775.76-30.03-36.09-0.7579.09
Gain (Loss) on Sale of Assets
4.736.411.33.672.030.51
Asset Writedown
-3.38-1.35-4.68-0.31-0.8-6.26
Other Unusual Items
4.764.767.5211.929.933.2
Pretax Income
186.78174.45135.95132.59155.21222.96
Income Tax Expense
80.0970.9246.5934.0348.5371.75
Earnings From Continuing Operations
106.7103.5389.3598.55106.68151.21
Minority Interest in Earnings
5.8410.3117.96.34.11
Net Income
112.54113.83100.35106.45112.99155.32
Net Income to Common
112.54113.83100.35106.45112.99155.32
Net Income Growth
50.56%13.43%-5.73%-5.78%-27.26%-
Shares Outstanding (Basic)
466455456463471471
Shares Outstanding (Diluted)
466455456463471471
Shares Change
3.95%-0.18%-1.45%-1.69%0.02%0.17%
EPS (Basic)
0.240.250.220.230.240.33
EPS (Diluted)
0.240.250.220.230.240.33
EPS Growth
44.84%13.64%-4.35%-4.17%-27.27%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
251.49264.07217.87210.4162.7193.22
Free Cash Flow Per Share
0.540.580.480.460.350.41
Gross Margin
70.24%68.47%68.61%68.23%67.18%69.14%
Operating Margin
12.08%10.53%10.29%8.69%9.19%8.11%
Profit Margin
8.18%7.82%6.33%6.70%7.27%10.12%
Free Cash Flow Margin
18.28%18.15%13.74%13.23%10.46%12.58%
EBITDA
229.57250.27305.17281.74253.74227.35
EBITDA Margin
16.69%17.20%19.25%17.72%16.32%14.81%
D&A For EBITDA
63.4397.09141.97143.6110.81102.91
EBIT
166.14153.18163.2138.14142.93124.44
EBIT Margin
12.08%10.53%10.29%8.69%9.19%8.11%
Effective Tax Rate
42.88%40.65%34.27%25.67%31.26%32.18%
Revenue as Reported
1,3751,4551,5851,5901,5551,535
Advertising Expenses
-26.5330.8632.9829.0232.43